Annals of Surgical Oncology

, Volume 26, Issue 11, pp 3586–3592 | Cite as

Distinct Clinical Manifestations of Thyroid Cancer After Hematopoietic Stem Cell Transplantation

  • Tae Yoon Lee
  • Sohee LeeEmail author
  • Ja Seong Bae
  • Woo-Chan Park
  • Sung-Soo Park
  • Sung-Eun Lee
  • Jong Wook Lee
  • Seong Koo Kim
  • Bin Cho
  • Chan Kwon Jung
Endocrine Tumors



The incidence of a secondary solid malignancy after hematopoietic cell transplantation (HCT) is increasing in long-term survivors.


The aim of this study was to compare the clinicopathological characteristics of HCT recipients with secondary thyroid cancer (STC), with those of non-HCT thyroid cancer patients.


We retrospectively investigated 5184 patients who received HCT between 1983 and 2016. Of these, 18 patients developed STC and underwent thyroidectomy due to differentiated thyroid cancer. We compared the clinicopathological characteristics of post-HCT thyroid cancer patients (post-HCT group) with those of a primary differentiated thyroid carcinoma cohort (cohort group) from Seoul St. Mary’s Hospital.


The mean ages at HCT and thyroidectomy after HCT were 22.0 and 31.8 years, respectively, and the median time interval between HCT and thyroidectomy was 5 years (range 1–16). Compared with the cohort group, the post-HCT group was younger at cancer onset and frequently had a palpable mass at initial diagnosis. The post-HCT group had more aggressive features, including larger tumor size, frequent extrathyroidal extension, lymphatic invasion, perineural invasion, and frequent lateral neck node metastasis and distant metastasis, relative to the cohort group; however, most patients (83.2%) in the post-HCT group were stage I or II. Additionally, BRAF V600E mutation was less frequent in the post-HCT group.


We found that STC after HCT showed younger presentation and more aggressive clinical presentation. Therefore, a policy of regular screening, including neck ultrasound examination, may promote early detection and treatment in HCT recipients.



The authors declare that they have no conflict of interest.

Supplementary material

10434_2019_7442_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 20 kb)
10434_2019_7442_MOESM2_ESM.docx (21 kb)
Supplementary material 2 (DOCX 20 kb)


  1. 1.
    Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19(2):464–71.CrossRefPubMedGoogle Scholar
  2. 2.
    Majhail NS, Tao L, Bredeson C, et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transpl. 2013;19(10):1498–1501.CrossRefGoogle Scholar
  3. 3.
    Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102(4):614–25.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bresters D, Lawitschka A, Cugno C, et al. Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. Bone Marrow Transplant. 2016;51(11):1482–89.CrossRefPubMedGoogle Scholar
  5. 5.
    Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336(13):897–904.CrossRefPubMedGoogle Scholar
  6. 6.
    Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 1998;91(6):1833–44.PubMedGoogle Scholar
  7. 7.
    Socié G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18(2):348–57.CrossRefPubMedGoogle Scholar
  8. 8.
    Cohen A, Rovelli A, van Lint MT, et al. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood. Bone Marrow Transplant. 2001;28(12):1125–28.CrossRefPubMedGoogle Scholar
  9. 9.
    Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007;25(17):2449–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175–83.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Danner-Koptik KE, Majhail NS, Brazauskas R, et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant. 2013;48(3):363–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Inamoto Y, Shah NN, Savani BN, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(8):1013–23.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Nelson AS, Ashton LJ, Vajdic CM, et al. Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy. Leukemia. 2015;29(2):441–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, Shaw BE. Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51(1):83–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Cohen A, Bekassy AN, Gaiero A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant. 2008;41 Suppl 2:S43–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med. 1996;156(19):2165–72.CrossRefPubMedGoogle Scholar
  17. 17.
    American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.Google Scholar
  18. 18.
    Jung CK, Im SY, Kang YJ, et al. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid. 2012;22(8):791–7.CrossRefPubMedGoogle Scholar
  19. 19.
    American Joint Committee on Cancer. AJCC Cancer Staging Manual, 7th edn, Springer; 2010. pp. 87–7.Google Scholar
  20. 20.
    Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”—screening and overdiagnosis. N Engl J Med. 2014;371(19):1765–67.CrossRefPubMedGoogle Scholar
  21. 21.
    Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26(11):1535–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Ho WL, Zacharin MR. Thyroid carcinoma in children, adolescents and adults, both spontaneous and after childhood radiation exposure. Eur J Pediatr. 2016;175(5):677–83.CrossRefPubMedGoogle Scholar
  23. 23.
    Uderzo C, van Lint MT, Rovelli A, et al. Papillary thyroid carcinoma after total body irradiation. Arch Dis Child. 1994;71(3):256–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141(3):259–77.CrossRefPubMedGoogle Scholar
  25. 25.
    Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25(7):716–59.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Clement SC, Kremer LC, Links TP, et al. Is outcome of differentiated thyroid carcinoma influenced by tumor stage at diagnosis? Cancer Treat Rev. 2015;41(1):9–16.CrossRefPubMedGoogle Scholar
  27. 27.
    Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol. 2018;36(18):1831–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Silva-Vieira M, Carrilho Vaz S, Esteves S, et al. Second primary cancer in patients with differentiated thyroid cancer: Does radioiodine play a role? Thyroid. 2017;27(8):1068–76.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Tae Yoon Lee
    • 1
  • Sohee Lee
    • 1
    Email author
  • Ja Seong Bae
    • 1
  • Woo-Chan Park
    • 1
  • Sung-Soo Park
    • 2
  • Sung-Eun Lee
    • 2
  • Jong Wook Lee
    • 2
  • Seong Koo Kim
    • 3
  • Bin Cho
    • 3
  • Chan Kwon Jung
    • 4
  1. 1.Department of Surgery, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  2. 2.Department of Hematology, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  3. 3.Department of Pediatrics, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  4. 4.Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea

Personalised recommendations